Exclusive Video Q&A With Timothy M. Mayleben, CEO of Aastrom Biosciences
10 April 2012 - 12:45AM
Marketwired
Last month, Aastrom Biosciences, Inc. (NASDAQ: ASTM) announced that
it had completed an impressive, $40 million private placement
financing. The development was noted as a particularly bullish sign
for emerging biotechs everywhere.
In an exclusive interview, Timothy Mayleben, who has served as
Aastrom's President and CEO since late 2009, explains how the
financing came to be and why investors sought out his firm to place
the big bet on their future.
Aastrom Biosciences is a regenerative medicine company engaged
in the development of autologous cell products for treatment of
severe, chronic cardiovascular diseases. Their proprietary
cell-processing technology enables the manufacture of ixmyelocel-T,
a patient-specific multicellular therapy expanded from a patient's
own bone marrow and delivered directly to damaged tissues. The
cellular therapy resulting from this process contains expanded
populations of mixed stem and progenitor cells to support the
regeneration of cardiovascular tissue. The company's cell
manufacturing process works exclusively with adult stem cells
derived from and administered to the same patient. This approach
reduces the risk of rejection and increases the likelihood of
integration with the surrounding tissues, eliminating the need for
immunosuppressive drugs.
Mayleben's exclusive interview with BioMedReports is now
available at:
http://www.biomedreports.com/2012040992513/qaa-timothy-mayleben-ceo-of-aastrom-biosciences.html
Healthcare investors and Biotech traders interested in accessing
BioMedReports' new complete database of clinical trials and
upcoming FDA and world-wide regulatory decisions which can be used
to make more profitable trades and see upcoming catalysts can go
to:
http://biomedreports.com/fdacal.html
News developments and live healthcare sector updates are
available constantly via Twitter at:
http://twitter.com/BioMedReports
About BioMedReports.Com
BioMedReports is a news and research portal covering financial
biomedical news and the entire Healthcare Sector of the market.
BioMedReports is not paid or compensated to report the news and
developments of publicly traded companies. They sell a premium
product for subscribers and full disclosures and information about
the stocks and news mentioned in this news release is available at
BioMedReports.Com
Add to Digg Bookmark with del.icio.us Add to Newsvine
Media Contacts Only: Mary Davila Assistant Editor
BioMedReports.Com e-mail: Email Contact Tel: +1 323 472 4480 Fax:
+1 888 210 3556
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024